Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms RE-FIT
- Sponsors Bristol-Myers Squibb
- 13 Jul 2017 Planned End Date changed from 1 Jan 2018 to 31 Jan 2018.
- 13 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 31 Jan 2018.
- 13 Jul 2017 Status changed from not yet recruiting to active, no longer recruiting.